OrthoPediatrics Beheer

Beheer criteriumcontroles 2/4

De CEO OrthoPediatrics is David Bailey, benoemd in Jun2020, heeft een ambtstermijn van 4.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.72M, bestaande uit 18.4% salaris en 81.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.95% van de aandelen van het bedrijf, ter waarde € 4.95M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.1 jaar en 12.8 jaar.

Belangrijke informatie

David Bailey

Algemeen directeur

US$2.7m

Totale compensatie

Percentage CEO-salaris	18.4%
Dienstverband CEO	4.4yrs
Eigendom CEO	0.9%
Management gemiddelde ambtstermijn	4.1yrs
Gemiddelde ambtstermijn bestuur	12.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is David Bailey's beloning veranderd ten opzichte van OrthoPediatrics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$28m
Jun 30 2024	n/a	n/a	-US$25m
Mar 31 2024	n/a	n/a	-US$22m
Dec 31 2023	US$3m	US$500k	-US$21m
Sep 30 2023	n/a	n/a	-US$22m
Jun 30 2023	n/a	n/a	US$976k
Mar 31 2023	n/a	n/a	US$4m
Dec 31 2022	US$1m	US$415k	US$1m
Sep 30 2022	n/a	n/a	US$9m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$906k	US$371k	-US$16m
Sep 30 2021	n/a	n/a	-US$30m
Jun 30 2021	n/a	n/a	-US$33m
Mar 31 2021	n/a	n/a	-US$38m
Dec 31 2020	US$898k	US$371k	-US$33m
Sep 30 2020	n/a	n/a	-US$23m
Jun 30 2020	n/a	n/a	-US$22m
Mar 31 2020	n/a	n/a	-US$15m
Dec 31 2019	US$836k	US$300k	-US$13m
Sep 30 2019	n/a	n/a	-US$11m
Jun 30 2019	n/a	n/a	-US$10m
Mar 31 2019	n/a	n/a	-US$10m
Dec 31 2018	US$590k	US$266k	-US$12m
Sep 30 2018	n/a	n/a	-US$25m
Jun 30 2018	n/a	n/a	-US$26m
Mar 31 2018	n/a	n/a	-US$26m
Dec 31 2017	US$483k	US$258k	-US$24m

Compensatie versus markt: De totale vergoeding ($USD 2.72M ) David } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.04M ).

Compensatie versus inkomsten: De vergoeding van David is gestegen terwijl het bedrijf verliesgevend is.

CEO

David Bailey (45 yo)

4.4yrs

Tenure

US$2,721,840

Compensatie

Mr. David R. Bailey serves as the Chief Executive Officer at OrthoPediatrics Corp. since June 01, 2021. He serves as the President at OrthoPediatrics Corp. since June 3, 2020 and serves as its Director sin...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mark Throdahl	Executive Chairman	15.8yrs	geen gegevens	0.75% € 3.9m
David Bailey	President	4.4yrs	US$2.72m	0.95% € 5.0m
Fred Hite	CFO, Principal Financial & Accounting Officer	9.8yrs	US$2.04m	0.62% € 3.3m
Daniel Gerritzen	Executive VP of Legal	15.8yrs	US$1.35m	0.32% € 1.7m
Gregory Odle	President of Scoliosis	no data	US$1.35m	0.48% € 2.5m
Kevin Unger	President of Enabling Technologies	1.5yrs	US$22.50k	geen gegevens
Joseph Hauser	President of Trauma & Deformity Correction	3.8yrs	US$1.35m	0.37% € 2.0m
Joel Batts	Senior Vice President of Clinical & Regulatory Affairs	2.1yrs	geen gegevens	geen gegevens
Mark Karshner	Senior Vice President of International Sales	8.8yrs	geen gegevens	geen gegevens

4.1yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 2X7 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Mark Throdahl	Executive Chairman	15.8yrs	geen gegevens	0.75% € 3.9m
David Bailey	President	3yrs	US$2.72m	0.95% € 5.0m
Fred Hite	CFO, Principal Financial & Accounting Officer	9.3yrs	US$2.04m	0.62% € 3.3m
Terry Schlotterback	Lead Independent Director	15.8yrs	US$185.00k	0.086% € 447.6k
Peter Armstrong	Chair of Surgeon Advisory Board	no data	geen gegevens	geen gegevens
David Pelizzon	Director	13.8yrs	US$180.00k	0.10% € 529.1k
Bryan Hughes	Independent Director	12.8yrs	US$190.00k	0.053% € 276.5k
Henry Chambers	Member of Surgeon Advisory Board	no data	geen gegevens	geen gegevens
J. Gordon	Member of Surgeon Advisory Board	no data	geen gegevens	geen gegevens
H. Graham	Member of Surgeon Advisory Board	no data	geen gegevens	geen gegevens
Daniel Hoernschemeyer	Member of Surgeon Advisory Board	no data	geen gegevens	geen gegevens
Marie Infante	Independent Director	10.8yrs	US$185.00k	0.047% € 244.9k

12.8yrs

Gemiddelde duur

68yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 2X7 zijn ervaren en ervaren (gemiddelde ambtstermijn van 12.8 jaar).

OrthoPediatrics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Executive VP of Legal recently sold €263k worth of stock

OrthoPediatrics Corp., Annual General Meeting, May 24, 2024

President recently sold €81k worth of stock

Key Executive recently sold €174k worth of stock

OrthoPediatrics Corp. Announces Election of George Dyer to its Board of Directors

Insider recently sold €105k worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.34 loss per share (vs US$0.20 loss in 3Q 2023)

OrthoPediatrics Corp. Increases Earnings Guidance for the Full Year 2024

OrthoPediatrics Corp. to Report Q3, 2024 Results on Nov 06, 2024

Executive VP of Legal recently sold €263k worth of stock

Second quarter 2024 earnings released: US$0.26 loss per share (vs US$0.13 loss in 2Q 2023)

Orthopediatrics Corp. Reiterates Revenue Guidance for the Year 2024

New minor risk - Share price stability

OrthoPediatrics Corp. to Report Q2, 2024 Results on Aug 05, 2024

New minor risk - Shareholder dilution

OrthoPediatrics Corp. Revises Revenue Guidance for the Full Year 2024

First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.30 loss in 1Q 2023)

OrthoPediatrics Corp. Receives Breakthrough Device” Designation from FDA for eLLi Growing Rod System for Pediatric Patients with Scoliosis

OrthoPediatrics Corp. to Report Q1, 2024 Results on May 06, 2024

OrthoPediatrics Corp., Annual General Meeting, May 24, 2024

New minor risk - Share price stability

President recently sold €81k worth of stock

New minor risk - Shareholder dilution

Orthopediatrics Corp. Reiterates Revenue Guidance for Full Year 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: US$0.93 loss per share (vs US$0.06 profit in FY 2022)

Orthopediatrics Corp. Provides Revenue Guidance for Full Year 2024

OrthoPediatrics Corp. Launches New RESPONSE Rib and Pelvic Fixation System for EOS Scoliosis

OrthoPediatrics Corp. to Report Q4, 2023 Results on Mar 06, 2024

OrthoPediatrics Corp. Provides Preliminary Unaudited Revenue Guidance Fourth Quarter and Full Year 2023 and for the Year 2024

New minor risk - Share price stability

OrthoPediatrics Corp. Reiterates Earnings Guidance for the Full Year of 2023

Third quarter 2023 earnings released: US$0.20 loss per share (vs US$0.88 profit in 3Q 2022)

New minor risk - Profitability

New minor risk - Shareholder dilution

OrthoPediatrics Corp. to Report Q3, 2023 Results on Nov 06, 2023

OrthoPediatrics Corp. Launches DF2 Brace

OrthoPediatrics Corp. Reiterates Earnings Guidance for the Full Year of 2023

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.017 loss in 2Q 2022)

OrthoPediatrics Corp. Announces the Launch and First Case Using the GIRO Growth Modulation System

Key Executive recently sold €174k worth of stock

OrthoPediatrics Corp. Announces Election of George Dyer to its Board of Directors

OrthoPediatrics Corp. Announces Launch of Response Power Scoliosis System

First quarter 2023 earnings released: US$0.30 loss per share (vs US$0.47 loss in 1Q 2022)

Insider recently sold €105k worth of stock

Full year 2022 earnings released: EPS: US$0.061 (vs US$0.84 loss in FY 2021)

OrthoPediatrics Corp. to Report Q4, 2022 Results on Feb 28, 2023

OrthoPediatrics Corp. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022 and Fiscal Year 2023

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: US$0.88 (vs US$0.11 loss in 3Q 2021)

OrthoPediatrics Corp. Updates Revenue Guidance for the Year 2022

Less than half of directors are independent

Orthopediatrics Corp. Announces Retirement of Stephen F. Burns from Board of Directors

OrthoPediatrics Corp. to Report Q3, 2022 Results on Oct 31, 2022

OrthoPediatrics Corp. has completed a Follow-on Equity Offering in the amount of $125.124619 million.

Second quarter 2022 earnings released: US$0.017 loss per share (vs US$0.20 loss in 2Q 2021)

OrthoPediatrics Corp. Revises Revenue Guidance for the Year 2022

OrthoPediatrics Corp. to Report Q2, 2022 Results on Aug 03, 2022

OrthoPediatrics Corp. (NasdaqGM:KIDS) and OrthoPediatrics Canada ULC completed the acquisition of Pega Medical Inc. for CAD 33 million.

OrthoPediatrics Corp. announced that it has received $50 million in funding from Squadron Capital, LLC

No longer forecast to breakeven

First quarter 2022 earnings released: US$0.47 loss per share (vs US$0.54 loss in 1Q 2021)

Orthopediatrics Corp. Provides Revenue Guidance for the Full Year 2022

OrthoPediatrics Corp. to Report Q1, 2022 Results on May 04, 2022

OrthoPediatrics Corp. (NasdaqGM:KIDS) acquired MD Orthopaedics, Inc. from John Mitchell for $19.6 million.

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Executive Chairman recently sold €315k worth of stock

OrthoPediatrics Corp. Announces Revenue Guidance for the Full Year 2022

OrthoPediatrics Corp. to Report Q4, 2021 Results on Mar 02, 2022

OrthoPediatrics Corp. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2021

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.24 loss in 3Q 2020)

Insider recently sold €55k worth of stock

Second quarter 2021 earnings released: US$0.20 loss per share (vs US$0.54 loss in 2Q 2020)

High number of new directors